Skip to content
Adrienne Monson – Lifestyle
Author:
Cellectis Inc.
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
June 9, 2026
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
May 20, 2026
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
May 12, 2026
Cellectis Reports Financial Results for the First Quarter 2026
May 11, 2026
Cellectis to Report First Quarter Financial Results on May 11, 2026
May 4, 2026
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
April 27, 2026
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
April 13, 2026
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
March 12, 2026